Comparing Factor Use and Bleed Rates in US Hemophilia A Patients Receiving Prophylaxis With 3 Different Long-Acting Recombinant Factor VIII Products
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the FDA's Peptide Reversal
2
Student Mental Health, Success Tied to Future Health and Affordability
3
FDA Approves First Orexin Agonist for Narcolepsy Type 1
4
Mobile Integrated Health Valuable in Heart Failure, but Payment Lags
5